Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 10/20 | 0.79 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.74 |
| ▸ | SLC10A2 | Q12908 | 2/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.74 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.74 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.74 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.74 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.74 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.74 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
| ▸ | CA1 | P00915 | 3/20 | 0.69 |
| ▸ | CA2 | P00918 | 3/20 | 0.69 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5499915 | 1.00 | GPBAR1 (0.79) | GPBAR1NR1H4MEN1KMT2AABCB11 | |
| SCHEMBL19360955 | 0.93 | GPBAR1 (0.79) | GPBAR1NR1H4MEN1KMT2AABCB11 | |
| SCHEMBL19360886 | 0.93 | GPBAR1 (0.79) | GPBAR1NR1H4MEN1KMT2AABCB11 | |
| SCHEMBL19360880 | 0.92 | GPBAR1 (0.85) | GPBAR1NR1H4MEN1KMT2AABCB11 | |
| SCHEMBL25943237 | 0.92 | GPBAR1 (0.85) | GPBAR1NR1H4MEN1KMT2AABCB11 | |
| SCHEMBL26424137 | 0.91 | GPBAR1 (0.76) | GPBAR1NR1H4MEN1KMT2AABCB11 | |
| SCHEMBL9465939 | 0.91 | GPBAR1 (0.76) | GPBAR1NR1H4MEN1KMT2AABCB11 | |
| Cholic Acid Ethyl Esters SCHEMBL24998394 | 0.90 | GPBAR1 (0.82) | GPBAR1NR1H4MEN1KMT2AABCB11 | |
| Cholic Acid Ethyl Esters SCHEMBL19685160 | 0.90 | GPBAR1 (0.82) | GPBAR1NR1H4MEN1KMT2AABCB11 | |
| SCHEMBL10511570 | 0.89 | GPBAR1 (0.86) | GPBAR1NR1H4MEN1KMT2AABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3593143-B1 | A SCREENING METHOD FOR CEREBROTENDINOUS XANTHOMATOSIS USING BILE ALCOHOL GLUCURONIDES AND METABOLITE RATIOS | Stichting Amsterdam UMC (NL) | 2024-11-27 | — | — | EP | claimed |
| CN-110612448-B | Method for screening for xanthomatosis of brain tendons using ratio of bile alcohol glucuronide and metabolite | 阿姆斯特丹大学学术医学中心 | 2023-06-13 | — | — | CN | claimed |
| US-11650212-B2 | Screening method for cerebrotendinous xanthomatosis using bile alcohol glucuronides and metabolite ratios | ACADEMISCH MEDISCH CENTRUM (NL) | 2023-05-16 | — | — | US | claimed |
| US-20210033626-A1 | A SCREENING METHOD FOR CEREBROTENDINOUS XANTHOMATOSIS USING BILE ALCOHOL GLUCURONIDES AND METABOLITE RATIOS | Stichting Amsterdam UMC (NL) | 2021-02-04 | — | — | US | claimed |
| CN-110612448-A | Method for screening brain tendon xanthomatosis using ratio of bile alcohol glucuronide to metabolite | 阿姆斯特丹大学学术医学中心 | 2019-12-24 | — | — | CN | claimed |
| WO-2018162362-A1 | A SCREENING METHOD FOR CEREBROTENDINOUS XANTHOMATOSIS USING BILE ALCOHOL GLUCURONIDES AND METABOLITE RATIOS | ACADEMISCH MEDISCH CENTRUM (NL) | 2018-09-13 | — | — | WO | claimed |
| US-20260062565-A1 | SELF-DISINFECTING AND PATHOGEN ERADICATING COATING WITH SPORE GERMINATION AGENT, ARTICLE COMPRISING THE COATING AND METHOD OF APPLICATION | KISMET TECH INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250345398-A1 | AGENTS AND METHODS FOR TREATING DISEASE | BIOXEL, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| EP-4620486-A1 | CONJUGATES OF G-PROTEIN COUPLED RECEPTOR AGONISTS AND ANTAGONISTS | Bioxel, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-4551257-A2 | SELF-DISINFECTING AND PATHOGEN ERADICATING COATING WITH SPORE GERMINATION AGENT, ARTICLE COMPRISING THE COATING, AND METHOD OF APPLICATION | Kismet Technologies Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| EP-3593143-B1 | A SCREENING METHOD FOR CEREBROTENDINOUS XANTHOMATOSIS USING BILE ALCOHOL GLUCURONIDES AND METABOLITE RATIOS | Stichting Amsterdam UMC (NL) | 2024-11-27 | — | — | EP | disclosed |
| US-20240216444-A1 | DESIGNED BACTERIAL COMPOSITIONS | SERES THERAPEUTICS, INC. (US) | 2024-07-04 | — | — | US | disclosed |
| WO-2024044256-A9 | SELF-DISINFECTING AND PATHOGEN ERADICATING COATING WITH SPORE GERMINATION AGENT, ARTICLE COMPRISING THE COATING, AND METHOD OF APPLICATION | KISMET TECHNOLOGIES LLC (US) | 2024-05-02 | — | — | WO | disclosed |
| EP-3380108-B1 | DESIGNED BACTERIAL COMPOSITIONS | SERES THERAPEUTICS INC (US) | 2022-11-16 | — | — | EP | disclosed |
| EP-4058031-A1 | SYNTHETIC COMPOSITION FOR BALANCING THE BILE ACID PROFILE IN THE INTESTINE | Glycom A/S (DK) | 2022-09-21 | — | — | EP | disclosed |
| US-20210033626-A1 | A SCREENING METHOD FOR CEREBROTENDINOUS XANTHOMATOSIS USING BILE ALCOHOL GLUCURONIDES AND METABOLITE RATIOS | Stichting Amsterdam UMC (NL) | 2021-02-04 | — | — | US | disclosed |
| CN-110612448-A | Method for screening brain tendon xanthomatosis using ratio of bile alcohol glucuronide to metabolite | 阿姆斯特丹大学学术医学中心 | 2019-12-24 | — | — | CN | disclosed |
| US-20190247447-A1 | DESIGNED BACTERIAL COMPOSITIONS | SERES THERAPEUTICS, INC. | 2019-08-15 | — | — | US | disclosed |
| WO-2018162362-A1 | A SCREENING METHOD FOR CEREBROTENDINOUS XANTHOMATOSIS USING BILE ALCOHOL GLUCURONIDES AND METABOLITE RATIOS | ACADEMISCH MEDISCH CENTRUM (NL) | 2018-09-13 | — | — | WO | disclosed |
| WO-2017223409-A1 | DIAGNOSTIC AND THERAPEUTIC METHODS RELATED TO INFLAMMATORY BOWEL DISEASES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062565-A1 | SELF-DISINFECTING AND PATHOGEN ERADICATING COATING WITH SPORE GERMINATION AGENT, ARTICLE COMPRISING THE COATING AND METHOD OF APPLICATION | POLR1C, CD63, CD4 | GPBAR1 4605/4885NR1H4 4804/4885MEN1 1680/4885 |
| US-20250345398-A1 | AGENTS AND METHODS FOR TREATING DISEASE | ARRB1, GPR68, GPBAR1 | GPBAR1 3/4885NR1H4 60/4885MEN1 4078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.